Home > Insider Trading > Filing (0001104659-23-079700)

Filing Details

Accession Number:: 0001104659-23-079700
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-07-10 17:01:03
Reporting Period:: 2023-07-10

Accepted Time:: 2023-07-10 17:01:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1621227	Adaptimmune Therapeutics Plc	ADAP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556064	E Garry Menzel	C/O Adaptimmune Therapeutics Plc 60 Jubilee Avenue, Milton Park Abingdon X0 OX14 4RX		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
American Depositary Shares Representing Ordinary Shares	Disposition	2023-07-10	47,702	$0.91	75,056	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of 100% of an RSU-style share option covering ordinary shares of the Issuer granted on July 5, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.9100 to $0.9211, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 611,224 ADSs and share options covering an aggregate of 11,093,593 ordinary shares of the Issuer. Included in the 611,224 ADSs are 200,646 ADSs held by the Garry E. Menzel Revocable Trust of 2022 (the "Menzel Trust") and 200,647 ADSs held by the Mary E. Henshall Revocable Trust of 2022 (the "Henshall Trust"). The Reporting Person is the trustee of the Menzel Trust and the Reporting Person's spouse is the trustee of the Henshall Trust and, as such, the Reporting Person may be deemed to beneficially own these securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust and the Henshall Trust.